MADISON, N.J. /eNewsChannels/ — NEWS Apr 19, 2013: Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.
Tag Archives | Drugs and Pharmaceuticals
Deanna Schwarz of Pfizer and CMI’s Paul Gondek and Alisa Hamilton to present at 2013 PRMG Annual National Conference
ATLANTA, Ga. /eNewsChannels/ — CMI and Pfizer Inc. (NYSE:PFE) will co-present ‘Engaging Stakeholders with A Story – 3 Tips to Improve Research Reporting’ at the PMRG’s upcoming National Annual Conference March 10-12, 2013 in National Harbor, Maryland.
ATLANTA, Ga. /eNewsChannels/ — CMI Research, a leader in marketing research services and insight, announced today that Beth Thompson has joined as Vice President, Qualitative Research. Thompson brings a 20-year track record of successfully conducting highly complex domestic and global marketing research.
BRIDGEPORT, Conn. /eNewsChannels/ — In the early 1980’s George Coleman, head of Dermedics Laboratories in Bridgeport, Conn., teamed up with the former Keneric Industries to reformulate and market an over-the-counter pharmaceutical product designed to treat the symptoms of hangovers. The product, Dr. Seltzer’s Hangover Helper, went on to become the best-selling hangover remedy in the U.S. It was eventually sold to a well-known manufacturer and, after almost 20 years on the market, was discontinued when that manufacturer was sold.
HIGHLAND PARK, N.J. /eNewsChannels/ — 2012 marks an important milestone for Belvidere Pharmacy. It opened new doors in its new hometown of Highland Park. When owner and President Shara Rudner, R.Ph. took the reins of the business in 1996, it was a typical retail pharmacy stocked with everything from school to surgical supplies. But from the beginning, Belvidere’s staff handled requests for compounded, or custom-made, medications from veterinarians, physicians and specialists.
Reaction Biology today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain
MALVERN, Pa. /eNewsChannels/ — Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology.
MALVERN, Pa. /eNewsChannels/ — Reaction Biology Corporation (‘RBC’), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.
REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA
SAN MARINO, Calif. /eNewsChannels/ — Epeius Bio announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.
Belvidere Pharmacy has secured the coveted Pharmacy Compounding Accreditation Board’s Seal of Accreditation
NORTH PLAINFIELD, N.J. /eNewsChannels/ — For the second time in its history, Belvidere Pharmacy of North Plainfield has secured the coveted Pharmacy Compounding Accreditation Board’s (PCAB) Seal of Accreditation. Registered in New York, New Jersey and Connecticut, Belvidere was the first and is still the only accredited PCAB pharmacy in the New York metro area. It has held this distinction since 2007.
SAN MARINO, Calif. /eNewsChannels/ — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company’s lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant.
MALVERN, Pa. — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.
SAN MARINO, Calif. — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances.
ASCO 2010: Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma
SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled ‘Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma’ at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.
Epeius Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer
SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announces the clinical results of the study entitled ‘A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.
SAN MARINO, Calif. — Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled ‘Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer’ (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA.
- Phil Rasori of MCT Trading, Inc. named to Annual Top 40 Under 40 List by National Mortgage Professional Mag Thu, 29 Jan 2015
- Delta Sigma Theta Sorority Sacramento Founders Day Celebration to feature Daphne Maxwell Reid Thu, 29 Jan 2015
- Former N.Y. Jet and Marine Wayne Wicka pens autobiography inspired by time with Coach Pete Carroll and New England Patriots Thu, 29 Jan 2015
- Melissa Stiwinter receives the 2014 Georgia Crump Certified Nursing Assistant Recognition Award in N.C. Thu, 29 Jan 2015
- Healthcare Insights LLC’s solution, INSIGHTS, Earns Fourth KLAS No.1 Budgeting Software Distinction Thu, 29 Jan 2015
- Opinion: Sincerely-Held Beliefs – Religiosity is an odious mistake of candidates from both major political parties Wed, 28 Jan 2015
- IMAGINE: Earthrising in 2015 Through Love Songs! Wed, 28 Jan 2015
- Pro golfer John Daly signs endorsement deal with online retailer Rock Bottom Golf Mon, 20 Oct 2014
- Political Earthquake Super PAC Supports Governor Sarah Palin’s Leadership for America Thu, 08 Jan 2015
- Opinion: Conservatism Kills Wed, 08 Oct 2014
- EaseUS Software anounces its new Todo Backup 8.0 with New Backup Technology Fri, 19 Dec 2014
- The International Cat Association (TICA) show in Sacramento, Jan. 2015, welcomes Cory Chalmers, of Hoarder’s TV Show Tue, 23 Dec 2014
- EPIC’s rapidly growing Employer Services Platform welcomes Shelley Dawson, Jon Greenstein and John Gaffney Thu, 11 Dec 2014
- NCIT TransactAPI 2.0 is First Transaction Platform for Funding Portals, Broker-Dealers and Private Issuers Fri, 12 Dec 2014
- Opinion: Sincerely-Held Beliefs – Religiosity is an odious mistake of candidates from both major political parties
- Religiosity is an odious mistake of candidates from both major political parties but is...
- IMAGINE: Earthrising in 2015 Through Love Songs!
- EARTHRISING is a Series on How we can lift each other up higher and higher through harnessing...
- Opinion: GOP Presidential Candidates 2016
- Here at the headquarters of the Anti-Conservative Team, we were fortunate to gain an interview...